New York, May 08, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Rare Biomarkers Specimen Collection and Stabilization Industry" - https://www.reportlinker.com/p06032735/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Rare Biomarkers Specimen Collection and Stabilization Market to Reach $78.6 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Rare Biomarkers Specimen Collection and Stabilization estimated at US$31.6 Billion in the year 2022, is projected to reach a revised size of US$78.6 Billion by 2030, growing at aCAGR of 12.1% over the period 2022-2030. Circulating Cell Free DNA (ccfDNA), one of the segments analyzed in the report, is projected to record 11.2% CAGR and reach US$30.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Circulating Tumor Cells (CTCs) segment is readjusted to a revised 12.6% CAGR for the next 8-year period.
The U.S. Market is Estimated at $9.4 Billion, While China is Forecast to Grow at 11.2% CAGR
The Rare Biomarkers Specimen Collection and Stabilization market in the U.S. is estimated at US$9.4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.3 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.1% and 9.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 10% CAGR.
Select Competitors (Total 32 Featured)
- Advanced Cell Diagnostics, Inc.
- Agena Bioscience
- ANGLE plc
- ApoCell, Inc.
- AS One InternationalNTERNATIONAL
- BioChain Institute, Inc.
- Biolidics Limited
- Biomatrica
- Bio-Techne Corporation
- BioVision, Inc.
- Caltag Medsystems Limited
- Cytomark Ltd.
- DNA Genotek, Inc.
- Epic Sciences
- EpiGentek Group Inc.
- F. Hoffmann-La Roche Ltd
- Fluxion Biosciences, Inc.
- Geno Technology Inc.
- Genomax Technologies Pte Ltd.
- GILUPI GmbH
- LifeSpan BioSciences, Inc.
- MagBio Genomics Inc.
- Menarini Silicon Biosystems
- MyBioSource.com
- Norgen Biotek Corp.
- Novus Biologicals, LLC
- OraSure Technologies Inc.
- Precision for Medicine, Inc.
- Promega Corporation
- QIAGEN
- Rarecells Diagnostics SAS
- RareCyte, Inc.
- siemens Healthineers
- SiO2 Materials Science
- STEMCELL Technologies Inc.
- Streck, Inc.
- Thermo Fisher Scientific, Inc.
- Vortex Biosciences
- VyCAP B.V.
Read the full report: https://www.reportlinker.com/p06032735/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Rare Biomarkers Specimen Collection and Stabilization - Global
Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 2: World 8-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets for Years 2023 & 2030
Table 3: World Recent Past, Current & Future Analysis for
Circulating Cell Free DNA (ccfDNA) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 4: World 8-Year Perspective for Circulating Cell Free DNA
(ccfDNA) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2023 & 2030
Table 5: World Recent Past, Current & Future Analysis for
Circulating Tumor Cells (CTCs) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 6: World 8-Year Perspective for Circulating Tumor Cells
(CTCs) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for
Exosomes / Extracellular Vesicles by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 8: World 8-Year Perspective for Exosomes / Extracellular
Vesicles by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2023 & 2030
Table 9: World Recent Past, Current & Future Analysis for
Circulating Cell Free RNA (ccfRNA) / miRNA by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 10: World 8-Year Perspective for Circulating Cell Free
RNA (ccfRNA) / miRNA by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2023 & 2030
Table 11: World Recent Past, Current & Future Analysis for
Research by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR
Table 12: World 8-Year Perspective for Research by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for
Diagnostics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR
Table 14: World 8-Year Perspective for Diagnostics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2023 & 2030
Table 15: World Rare Biomarkers Specimen Collection and
Stabilization Market Analysis of Annual Sales in US$ Million
for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Rare Biomarkers Specimen Collection and Stabilization Market
Presence - Strong/Active/Niche/Trivial - Key Competitors in
the United States for 2023 (E)
Table 16: USA Recent Past, Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by Product
Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor
Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating
Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 17: USA 8-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by Product Type - Percentage
Breakdown of Value Sales for Circulating Cell Free DNA
(ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2023 & 2030
Table 18: USA Recent Past, Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by End-Use -
Research and Diagnostics - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR
Table 19: USA 8-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by End-Use - Percentage Breakdown
of Value Sales for Research and Diagnostics for the Years 2023 &
2030
CANADA
Table 20: Canada Recent Past, Current & Future Analysis for
Rare Biomarkers Specimen Collection and Stabilization by
Product Type - Circulating Cell Free DNA (ccfDNA), Circulating
Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and
Circulating Cell Free RNA (ccfRNA) / miRNA - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 21: Canada 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2023 & 2030
Table 22: Canada Recent Past, Current & Future Analysis for
Rare Biomarkers Specimen Collection and Stabilization by
End-Use - Research and Diagnostics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 23: Canada 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2023 & 2030
JAPAN
Rare Biomarkers Specimen Collection and Stabilization Market
Presence - Strong/Active/Niche/Trivial - Key Competitors in
Japan for 2023 (E)
Table 24: Japan Recent Past, Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by Product
Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor
Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating
Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 25: Japan 8-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by Product Type - Percentage
Breakdown of Value Sales for Circulating Cell Free DNA
(ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2023 & 2030
Table 26: Japan Recent Past, Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by End-Use -
Research and Diagnostics - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR
Table 27: Japan 8-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by End-Use - Percentage Breakdown
of Value Sales for Research and Diagnostics for the Years 2023 &
2030
CHINA
Rare Biomarkers Specimen Collection and Stabilization Market
Presence - Strong/Active/Niche/Trivial - Key Competitors in
China for 2023 (E)
Table 28: China Recent Past, Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by Product
Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor
Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating
Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 29: China 8-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by Product Type - Percentage
Breakdown of Value Sales for Circulating Cell Free DNA
(ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2023 & 2030
Table 30: China Recent Past, Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by End-Use -
Research and Diagnostics - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR
Table 31: China 8-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by End-Use - Percentage Breakdown
of Value Sales for Research and Diagnostics for the Years 2023 &
2030
EUROPE
Rare Biomarkers Specimen Collection and Stabilization Market
Presence - Strong/Active/Niche/Trivial - Key Competitors in
Europe for 2023 (E)
Table 32: Europe Recent Past, Current & Future Analysis for
Rare Biomarkers Specimen Collection and Stabilization by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 33: Europe 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Geographic Region -
Percentage Breakdown of Value Sales for France, Germany, Italy,
UK and Rest of Europe Markets for Years 2023 & 2030
Table 34: Europe Recent Past, Current & Future Analysis for
Rare Biomarkers Specimen Collection and Stabilization by
Product Type - Circulating Cell Free DNA (ccfDNA), Circulating
Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and
Circulating Cell Free RNA (ccfRNA) / miRNA - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 35: Europe 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2023 & 2030
Table 36: Europe Recent Past, Current & Future Analysis for
Rare Biomarkers Specimen Collection and Stabilization by
End-Use - Research and Diagnostics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 37: Europe 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2023 & 2030
FRANCE
Rare Biomarkers Specimen Collection and Stabilization Market
Presence - Strong/Active/Niche/Trivial - Key Competitors in
France for 2023 (E)
Table 38: France Recent Past, Current & Future Analysis for
Rare Biomarkers Specimen Collection and Stabilization by
Product Type - Circulating Cell Free DNA (ccfDNA), Circulating
Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and
Circulating Cell Free RNA (ccfRNA) / miRNA - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 39: France 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2023 & 2030
Table 40: France Recent Past, Current & Future Analysis for
Rare Biomarkers Specimen Collection and Stabilization by
End-Use - Research and Diagnostics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 41: France 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2023 & 2030
GERMANY
Rare Biomarkers Specimen Collection and Stabilization Market
Presence - Strong/Active/Niche/Trivial - Key Competitors in
Germany for 2023 (E)
Table 42: Germany Recent Past, Current & Future Analysis for
Rare Biomarkers Specimen Collection and Stabilization by
Product Type - Circulating Cell Free DNA (ccfDNA), Circulating
Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and
Circulating Cell Free RNA (ccfRNA) / miRNA - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 43: Germany 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2023 & 2030
Table 44: Germany Recent Past, Current & Future Analysis for
Rare Biomarkers Specimen Collection and Stabilization by
End-Use - Research and Diagnostics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 45: Germany 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2023 & 2030
ITALY
Table 46: Italy Recent Past, Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by Product
Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor
Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating
Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 47: Italy 8-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by Product Type - Percentage
Breakdown of Value Sales for Circulating Cell Free DNA
(ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2023 & 2030
Table 48: Italy Recent Past, Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by End-Use -
Research and Diagnostics - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR
Table 49: Italy 8-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by End-Use - Percentage Breakdown
of Value Sales for Research and Diagnostics for the Years 2023 &
2030
UNITED KINGDOM
Rare Biomarkers Specimen Collection and Stabilization Market
Presence - Strong/Active/Niche/Trivial - Key Competitors in
the United Kingdom for 2023 (E)
Table 50: UK Recent Past, Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by Product
Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor
Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating
Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 51: UK 8-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by Product Type - Percentage
Breakdown of Value Sales for Circulating Cell Free DNA
(ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2023 & 2030
Table 52: UK Recent Past, Current & Future Analysis for Rare
Biomarkers Specimen Collection and Stabilization by End-Use -
Research and Diagnostics - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR
Table 53: UK 8-Year Perspective for Rare Biomarkers Specimen
Collection and Stabilization by End-Use - Percentage Breakdown
of Value Sales for Research and Diagnostics for the Years 2023 &
2030
REST OF EUROPE
Table 54: Rest of Europe Recent Past, Current & Future Analysis
for Rare Biomarkers Specimen Collection and Stabilization by
Product Type - Circulating Cell Free DNA (ccfDNA), Circulating
Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and
Circulating Cell Free RNA (ccfRNA) / miRNA - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 55: Rest of Europe 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2023 & 2030
Table 56: Rest of Europe Recent Past, Current & Future Analysis
for Rare Biomarkers Specimen Collection and Stabilization by
End-Use - Research and Diagnostics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 57: Rest of Europe 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2023 & 2030
ASIA-PACIFIC
Rare Biomarkers Specimen Collection and Stabilization Market
Presence - Strong/Active/Niche/Trivial - Key Competitors in
Asia-Pacific for 2023 (E)
Table 58: Asia-Pacific Recent Past, Current & Future Analysis
for Rare Biomarkers Specimen Collection and Stabilization by
Product Type - Circulating Cell Free DNA (ccfDNA), Circulating
Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and
Circulating Cell Free RNA (ccfRNA) / miRNA - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 59: Asia-Pacific 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2023 & 2030
Table 60: Asia-Pacific Recent Past, Current & Future Analysis
for Rare Biomarkers Specimen Collection and Stabilization by
End-Use - Research and Diagnostics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 61: Asia-Pacific 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2023 & 2030
REST OF WORLD
Table 62: Rest of World Recent Past, Current & Future Analysis
for Rare Biomarkers Specimen Collection and Stabilization by
Product Type - Circulating Cell Free DNA (ccfDNA), Circulating
Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and
Circulating Cell Free RNA (ccfRNA) / miRNA - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 63: Rest of World 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by Product Type -
Percentage Breakdown of Value Sales for Circulating Cell Free
DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes /
Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) /
miRNA for the Years 2023 & 2030
Table 64: Rest of World Recent Past, Current & Future Analysis
for Rare Biomarkers Specimen Collection and Stabilization by
End-Use - Research and Diagnostics - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR
Table 65: Rest of World 8-Year Perspective for Rare Biomarkers
Specimen Collection and Stabilization by End-Use - Percentage
Breakdown of Value Sales for Research and Diagnostics for the
Years 2023 & 2030
IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06032735/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
